Drug-eluting stents

Coronary disease

Angioplasty in sirolimus – eluting stent restenosis is safe and effective beyond the change of drug.

Original title: Sirolimius-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stents restenosis: Results from the...

solaci - 6 May, 2014

Chronic Ischemic cardiopathy

Best results of angioplasty with DES guided by IVUS versus angiography only

Original title: Intravascular Ultrasound-Guided Implantation of Drug-Eluting Stents to Improve Outcome. A Meta-Analysis. Reference: Jae-Sik Jang et al. J Am...

solaci - 26 February, 2014

Antithrombotic Anticoagulants

At least one month of antiplatelet seems sufficient after a zotarolimus -eluting stent

Original title: Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months...

solaci - 25 February, 2014

Coronary disease

3rd generation zotarolimus-eluting stent non- inferior to everolimus

Original title: Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a...

solaci - 13 February, 2014

Chronic Ischemic cardiopathy

Malapposition in drug-eluting stents. Much more common and much less serious than we thought

Original title: Incidences, Predictors, and Clinical Outcomes of Acute and Late Stent Malapposition Detected by Optical Coherence Tomography...

solaci - 28 January, 2014

Acute coronary syndromes

Primary angioplasty with 2nd generation drug-eluting stents

Original title: Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: Network meta-analysis of primary percutaneous coronary...

solaci - 10 December, 2013

Coronary disease

Everolimus -eluting stent to 3 years, most security was the key difference.

Original title: Everolimus-eluting stents in patients undergoing percutaneous coronary Intervention: Final 3-year results of the Clinical Evaluation of...

solaci - 10 December, 2013

Coronary disease

Similar results of drug-eluting stents with biodegradable polymer versus permanent

Original title: Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting StentA Randomized, Controlled, Noninferiority Trial.NEXT trial. Reference: Masahiro Natsuaki et...

solaci - 15 November, 2013

Angioplasty in sirolimus – eluting stent restenosis is safe and effective beyond the change of drug.

Best results of angioplasty with DES guided by IVUS versus angiography only

At least one month of antiplatelet seems sufficient after a zotarolimus -eluting stent

3rd generation zotarolimus-eluting stent non- inferior to everolimus

Malapposition in drug-eluting stents. Much more common and much less serious than we thought

Primary angioplasty with 2nd generation drug-eluting stents

Everolimus -eluting stent to 3 years, most security was the key difference.

Similar results of drug-eluting stents with biodegradable polymer versus permanent

Últimas Noticias

Perforation Management in Bifurcations: Bench Testing of Bailout with Covered Stents

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Noticias Institucionales

SOLACI Wishes You Happy Holidays

Condolences on the passing of Cristiam Arancibia

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Accesos